Galectin Therapeutics Inc. | Mutual Funds
Mutual Funds that own Galectin Therapeutics Inc.
Vanguard Total Stock Market Index Fund
778,195
1.9%
42,200
0%
07/31/2018
Vanguard Extended Market Index Fund
395,955
0.97%
0
0%
07/31/2018
PowerShares DWA Small Cap Momentum Portfolio
202,893
0.5%
0
0.28%
09/05/2018
Fidelity Spartan Extended Market Index Fund
129,777
0.32%
0
0%
07/31/2018
iShares Micro Cap ETF
78,820
0.19%
0
0.05%
09/06/2018
Fidelity Spartan Total Market Index Fund
56,076
0.14%
0
0%
07/31/2018
Vanguard Institutional Total Stock Market Index Fund
40,091
0.1%
0
0%
07/31/2018
Vanguard Balanced Index Fund
21,181
0.05%
0
0%
07/31/2018
Fidelity Nasdaq Composite Index
16,710
0.04%
0
0%
07/31/2018
iShares Core S&P Total US Stock Market ETF
14,965
0.04%
0
0%
09/06/2018
| Address |
4960 Peachtree Industrial Boulevard
Norcross Georgia 30071
United States
|
|
Employees
|
- |
| Website |
http://www.galectintherapeutics.com |
| Updated |
07/08/2019 |
| Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs targets the development of carbohdrate molecules which offers offer alternative options to larger market segments. The company was founded by James C. |
